Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

UMN Pharma Inc lowers consolidated full-year outlook for FY 2013


Friday, 27 Dec 2013 04:00am EST 

UMN Pharma Inc:Sees consolidated full-year revenue of 93 million yen from 2,000 million yen for fiscal year 2013.Sees operating profit of a loss of 4,606 million yen from 1,900 million yen.Sees ordinary profit of a loss of 4,331 million yen from a loss of 2,100 million yen.Sees net profit of a loss of 3,894 million yen from a loss of 2,000 million yen.Sees earning per share of a loss of 515.02 yen from a loss of 277.58 yen.Says the negative outlook is due to the decreased sales and the increased cost. 

Company Quote

3350.0
-30.0 -0.89%
30 Jul 2014